Common questions about Feiba (FAQ)
Q: How quickly does Feiba start working?
Studies and official information indicate that the goal of stopping bleeding, known as hemostasis, was commonly recorded within the initial 36 hours after the start of treatment in the populations observed. This time frame reflects the period researchers tracked to determine if the treatment successfully achieved hemostasis.
Q: How long do the effects of Feiba last in the body?
Regulatory documents describe the treatment approach as aiming to achieve blood clot control. For acute bleeds, official guidance notes that doses are typically repeated at set intervals, such as every 6 or 12 hours, until a patient's clinical situation improves or the bleeding stops.
Q: Can Feiba be used for minor bleeds or only major ones?
Regulatory dosing guidelines provide recommendations for treating various categories of bleeding episodes, which include joint, muscle, and soft tissue hemorrhage. This indicates the medicine is indicated for use in managing a range of bleeds, from minor to moderately severe.
Q: Does Feiba interact with common over-the-counter pain relievers?
Official interaction documents focus primarily on interactions with other medicines that affect blood clotting, such as systemic antifibrinolytics and recombinant Factor VIIa. These documents do not specifically list or warn against common over-the-counter pain relievers such as acetaminophen or ibuprofen.
Q: What are the official warnings about using Feiba?
The official product information includes a Boxed Warning regarding the risk of Thromboembolic Events (TEEs), which are blood clots that can cause serious conditions like stroke or pulmonary embolism. Other warnings relate to the potential for severe allergic reactions (hypersensitivity) and the small theoretical risk of infectious agent transmission from the product's plasma origin.
Q: Is it safe to drive after having a Feiba infusion?
Official product information does not directly assess the medicine's effect on a person's ability to drive or use machinery. However, commonly reported side effects include dizziness and headache. Because of this, individuals should be cautious if experiencing symptoms that could affect their ability to drive or operate machinery.
Q: Do official documents specify if Feiba can cause nausea?
Yes, official safety information explicitly lists nausea as one of the most frequently reported adverse reactions observed during clinical trials. Nausea is documented as a common infusion-related effect reported by users of the product.
Q: Why is it important to keep track of my Feiba usage?
Official administration instructions emphasize the need for close monitoring by healthcare professionals during and after treatment for signs of adverse reactions. Additionally, regulations require providers to record the patient’s name and the specific batch number of the product to maintain a link between the user and the product for tracking and safety purposes.
Q: Can Feiba be given at home or only in a hospital setting?
The product is a powder requiring reconstitution and is administered by intravenous (IV) infusion. The official consumer information states that the injection should be prepared and administered by a qualified healthcare professional experienced in the care of patients with hemophilia.
Q: Are there studies comparing Feiba to alternative treatments for patients with inhibitors?
The official research overview notes a specific limitation in the evidence landscape. It states that comparative evidence is lacking from formal, large-scale, randomized trials that directly compare this treatment against other bypassing agents used for managing acute bleeding episodes.
Q: Does Feiba affect kidney or liver function?
Official regulatory documents do not list changes to kidney or liver function as a common side effect. However, the official label notes that pre-existing conditions, such as impaired liver function, are considerations for physicians when prescribing the medicine.
Q: What is the general success rate reported for Feiba in treating bleeds?
A pivotal trial evaluating the control of bleeding episodes reported specific outcomes in the observed population. Hemostasis (the control of bleeding) was reported to be achieved in 93% of the bleeding episodes treated, with 78% of those achieving clot control within the first 36 hours of treatment.
Q: Is it normal to feel a tingling sensation during the infusion?
Official safety information lists 'burning, crawling, itching, numbness, prickling, 'pins and needles', or tingling feelings' as reported adverse effects. This means that while it has been reported by some users, the exact frequency of this sensation is not estimated.
Q: Can Feiba be used in combination with other blood-related medicines?
Regulatory documents state that this product is not to be mixed with other medicinal products in the same tubing or container. Co-administration with certain other blood-related agents, such as systemic antifibrinolytics or recombinant Factor VIIa, carries specific warnings due to an increased risk of blood clots.
Q: Are there different doses of Feiba, and how are they generally determined?
Yes, regulatory documents describe different general dose ranges for acute bleeds versus routine prophylactic use. The specific dose and frequency a patient receives are generally determined by the type, location, and extent of the bleeding, as well as the patient’s individual response to treatment.
Q: Is it possible to receive too much Feiba?
Yes, official regulatory documents state that the maximum single dose must not exceed 100 U/kg, and the maximum daily dose must not exceed 200 U/kg. Receiving doses higher than these limits is associated with a potential increase in the risk of serious thromboembolic events (blood clots).
Q: Is Feiba treatment painful?
Official safety information lists pain in the injection site as one of the reported adverse effects. While various infusion-related reactions are commonly documented, the specific frequency of injection site pain is not estimated.
Q: Why might a doctor switch a patient from a different factor to Feiba?
The product is specifically indicated for patients with Hemophilia A or B who have developed inhibitors (antibodies) against their standard Factor VIII or Factor IX replacement therapies. The medicine contains factors designed to bypass the action of these inhibitors, helping the blood clot despite their presence.
Q: Is Feiba approved in countries outside of the United States?
Yes, this medicine is approved for use and has official labeling published by major regulatory bodies outside of the United States, including the European Medicines Agency (EMA) and the Therapeutic Goods Administration (TGA) of Australia.
Q: Is swelling or pain at the injection site a common problem with Feiba?
Official safety information lists pain in the injection site and joint pain, stiffness, or swelling as reported adverse effects. While various infusion-related reactions are commonly documented, the exact frequency of injection site-specific swelling or severe pain is not estimated in the official documents.
